Today: 19 April 2026
DroneShield stock slips 5% after broker-led rally; what to watch after the ASX holiday
23 January 2026
1 min read

DroneShield stock slips 5% after broker-led rally; what to watch after the ASX holiday

Sydney, Jan 23, 2026, 17:44 AEDT — Market closed

  • After soaring 9.5% yesterday, DroneShield shares slipped 5.5% to close at A$4.47.
  • Bell Potter raised its target to A$5, highlighting U.S. public safety spending as a catalyst in the near term
  • The ASX will be closed Monday for Australia Day, reopening Tuesday with attention on earnings schedules and contract flow.

DroneShield Limited (ASX:DRO) slipped 5.5% to close at A$4.47 on Friday, pulling back from Thursday’s 9.5% jump to A$4.73. The share price fluctuated between A$4.43 and A$4.69, with roughly 15.3 million shares traded.

The pullback came just a day after Bell Potter upgraded its view on the counter-drone developer, raising the target price to A$5 and highlighting a possible surge in defense spending. The broker flagged a potential A$2.5 billion sales pipeline and predicted significant contracts could arrive within three to six months, also mentioning ASX peers EOS Electro Optic and Elsight in the same “drone” sector. Finance News Network

“We see 2026 as a turning point for the global C-UAS market,” said Bell Potter analyst Baxter Kirk, referring to counter-uncrewed aircraft systems, the tech aimed at detecting and neutralizing drones. Capital Brief noted the broker pointed to US$250 million in funding tied to security at major U.S. events and raised its 12-month price target for DroneShield from A$4.40 to A$5. Capital Brief

DroneShield kept the news coming Wednesday, unveiling Q1 2026 software updates for its DroneSentry-C2 command-and-control suite and RfPatrol-Plugin. The upgrades are designed to streamline operations and enhance sensor coordination — what the industry calls “sensor fusion,” or merging data from various sensors into a single track. DroneShield

Looking ahead, the ASX cash market will shut down Monday in observance of Australia Day. Local traders won’t get a fresh read on prices until trading resumes Tuesday.

Investors have learned to watch that gap closely. DroneShield’s stock has been volatile since last year, following executive share sales and governance worries that shook confidence and sent the price tumbling, according to a November report by Reuters.

But the optimistic broker calculations come with a caveat. Defense and public safety orders often arrive in fits and starts, procurement schedules get pushed back, and chatter about a “pipeline” doesn’t always translate into signed deals — particularly as agencies weigh options among numerous radar, radio-frequency detection, and jamming vendors.

Traders eye the week ahead for contract news or guidance that could confirm—or challenge—the notion of near-term U.S. victories. MarketIndex’s company calendar pins DroneShield’s preliminary and annual reports to Feb. 24, marking the next key update for the stock.

Stock Market Today

  • Nordea Bank Abp's Mixed Share Performance and Valuation Analysis
    April 18, 2026, 10:42 PM EDT. Nordea Bank Abp (HLSE:NDA FI) exhibits mixed returns with a negative year-to-date but a 51.1% total return over one year, showing strong long-term momentum. The bank's share price closed at €16.02, slightly below the €16.55 analyst target and a fair value estimate of €17.03, suggesting it may be undervalued. Nordea is investing heavily in digital technologies and cybersecurity, aiming to improve net margins and fee income. However, potential risks include Nordic housing market weakness and rising regulatory costs. Investors are advised to weigh both upside potential and downside risks before making decisions, considering broader financial sector comparisons and market conditions.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week
Previous Story

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

Paytm share price whipsaws after Investec starts coverage with ‘Buy’ and ₹1,550 target
Next Story

Paytm share price whipsaws after Investec starts coverage with ‘Buy’ and ₹1,550 target

Go toTop